Tyrosine kinase inhibitorPhase 3 trialInvestigational
Lapatinib
How it works
Blocks the growth of cancer cells by inhibiting the HER2 and EGFR receptors.
Cancer types
Efficacy
Lapatinib has shown promise in improving progression-free survival in patients with HER2-positive ovarian cancer, but further studies are needed to confirm its efficacy.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Pyrotinib Plus Capecitabine May Improve Survival in HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Median overall survival was 74.61 months with pyrotinib plus capecitabine and 30.98 months with lapatinib plus capecitabine. | Source → |
| Evaluating a Combination Treatment for Older Adults with HER2 Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Understanding Lapatinib Resistance in HER2+ Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Treatment Combination Shows Promise for Advanced Breast Cancer | Breast Cancer | phase-3 | Treatment with pyrotinib plus capecitabine significantly improved overall survival compared with lapatinib plus capecitabine. | Source → |
| Combination of two drugs targets cancer cells in lab experiments | Pancreatic Cancer | lab-study | — | Source → |
| Lapatinib Efficacy in HER2 Positive Breast Cancer Patients | Breast Cancer | phase-2 | Median overall survival was 10.1 months in the group that received lapatinib after exposure to trastuzumab, pertuzumab and/or T-DM1, and 16.3 months in the group of patients who received lapatinib after trastuzumab. | Source → |
| Researchers Report Successful HER2 Targeting in Rare Colorectal Cancer Case | Colorectal Cancer | observational | Treatment with trastuzumab + lapatinib resulted in an excellent response that lasted for 10 months. | Source → |
| New Combination Therapy Shows Promise for Advanced Breast Cancer | Breast Cancer | phase-1 | Of evaluable patients, 4 demonstrated a partial response and 2 had stable disease. | Source → |
| IL-8 in Tumors May Reduce Effectiveness of Breast Cancer Drug | Breast Cancer | lab-study | — | Source → |
| Researchers Find New Way to Target Aggressive Breast Cancer | Breast Cancer | lab-study | Application of these inhibitors led to a 5.62-fold increase in the epithelial marker E-cadherin and a 3.33-fold decrease in the stemness marker EpCAM. | Source → |
| BCL-2 levels change in response to HER2-targeted therapy | Breast Cancer | phase-2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.